Scarica l'app Stockscreener
1.33
1.53%
0.02
Dopo l'orario di chiusura:
1.37
0.04
+3.01%
Precedente Chiudi:
$1.31
Aprire:
$1.3022
Volume 24 ore:
20,999
Relative Volume:
0.02
Capitalizzazione di mercato:
$901.18K
Reddito:
$1.22M
Utile/perdita netta:
$-3.26M
Rapporto P/E:
-0.2164
EPS:
-6.1455
Flusso di cassa netto:
$-6.38M
1 W Prestazione:
-14.19%
1M Prestazione:
-43.16%
6M Prestazione:
-77.83%
1 anno Prestazione:
-90.22%
Intervallo 1D:
$1.30
$1.37
Intervallo di 1 settimana:
$1.27
$1.57
Portata 52W:
$1.27
$16.30
Scinai Immunotherapeutics Ltd Adr Stock (SCNI) Company Profile
Nome
Scinai Immunotherapeutics Ltd Adr
Settore
Industria
Telefono
972-8-9302529
Indirizzo
JERUSALEM BIOPARK, 2ND FLOOR, JERUSALEM
Compare SCNI vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SCNI
Scinai Immunotherapeutics Ltd Adr
|
1.33 | 1.05M | 1.22M | -3.26M | -6.38M | -6.1455 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Scinai Immunotherapeutics Ltd Adr Borsa (SCNI) Ultime notizie
SCNIScinai Immunotherapeutics Ltd. | News - OTC Markets
Full issuance would represent about 66.67% of Scinai (SCNI)'s depositary shares under its funding deal. - Stock Titan
Scinai regains compliance with Nasdaq minimum bid price rule By Investing.com - Investing.com Nigeria
SCNI Stock Wobbles As Scinai Refocuses On NanoAb Platform - timothysykes.com
Scinai regains compliance with Nasdaq minimum bid price rule - Investing.com
Scinai Immunotherapeutics regains Nasdaq compliance - TipRanks
Why Veea Shares Are Trading Higher By 58%; Here Are 20 Stocks Moving Premarket - Benzinga
Why Scholar Rock Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Benzinga
Nasdaq Down Over 200 Points; Cellectis Shares Plunge - Benzinga
Scinai Immunotherapeutics (SCNI) Q4 2023 Earnings: Narrower-Than-Expected Loss of $0.47 Per ShareRetail Earnings Report - dars.gov.et
Scinai Immunotherapeutics refocuses capital on NanoAb platform and CDMO business - TipRanks
Scinai Concludes PC111 Arrangements and Refocuses Capital on NanoAb Platform and Growing CDMO Business - Barchart.com
Scinai (NASDAQ: SCNI) updates $15M equity deal that could dilute investors - Stock Titan
Earnings call transcript: Scinai posts H1 2026 revenue growth as losses persist - Investing.com Nigeria
Scinai reports H1 2026 results, announces U.S. customer expansion - Investing.com India
Scinai Immunotherapeutics (NASDAQ: SCNI): Why Is A recent reverse share split that reset the chart structure in Focus Now? - Kalkine Media
What Could Scinai Immunotherapeutics (NASDAQ:SCNI) Reveal Today About Its Next Operating Milestones? - Kalkine Media
Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration - Barchart.com
Scinai Immunotherapeutics Ltd. Sponsored ADR Actuals & Estimates (NASDAQ:SCNI) - TradingView
Price to sales forward of Scinai Immunotherapeutics Ltd. Sponsored ADR – MUN:2F5 - TradingView
Enterprise value to revenue forward of Scinai Immunotherapeutics Ltd. Sponsored ADR – MUN:2F5 - TradingView
Enterprise value to EBITDA forward of Scinai Immunotherapeutics Ltd. Sponsored ADR – MUN:2F5 - TradingView
Enterprise value to EBIT forward of Scinai Immunotherapeutics Ltd. Sponsored ADR – MUN:2F5 - TradingView
Why Scinai Immunotherapeutics stock is skyrocketing 90% higher today - MSN
Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives - Barchart.com
SCNI Technical Analysis | Trend, Signals & Chart Patterns | SCINAI IMMUNOTHERAPEUTICS LT (NASDAQ:SCNI) - ChartMill
Scinai appoints Eilon Elmalem as Yavne CDMO facility head - Investing.com
Scinai appoints Eilon Elmalem as Yavne CDMO facility head By Investing.com - Investing.com India
Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility - Barchart.com
Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe - Sahm
Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe - Benzinga
Scinai Immunotherapeutics schedules annual shareholder meeting for June 16 - Investing.com
NASDAQ gains over 100 points; Intel shares jump after strong Q1 results - MSN
Tangible book value per share of Scinai Immunotherapeutics Ltd. Sponsored ADR – FWB:2F5 - TradingView
Wedge DownStock ScreenerCharts - Finviz
Why Organon Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket - Benzinga
Why Scinai Immunotherapeutics Stock Is Skyrocketing 90% Higher Today - Sahm
Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing - Finviz
Nasdaq Gains Over 100 Points; Intel Shares Jump After Strong Q1 Results - Benzinga
Scinai raises $2.61M in private placement to expand CDMO unit - Investing.com
Scinai raises $2.61M in private placement to expand CDMO unit By Investing.com - Investing.com South Africa
Why TopBuild Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket - Sahm
Scinai Completes Corporate Reorganization Separating CDMO and R&D Operations - Contract Pharma
Scinai completes corporate reorganization, separates CDMO unit By Investing.com - Investing.com South Africa
Cash per share of Scinai Immunotherapeutics Ltd. Sponsored ADR – FWB:2F5 - TradingView
Total debt per share of Scinai Immunotherapeutics Ltd. Sponsored ADR – FWB:2F5 - TradingView
Scinai completes corporate reorganization, separates CDMO unit - Investing.com
Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities - Barchart.com
Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration - Sahm
Scinai Immunotherapeutics (NASDAQ: SCNI) details going concern, CDMO and NanoAb risks - Stock Titan
Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026 - Barchart.com
Scinai Immunotherapeutics Ltd Adr Azioni (SCNI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):